{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:43:52Z","timestamp":1792100632148,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vasdi.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:25Z","timestamp":1792097065000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin for primary prevention in patients with high lipoprotein(a): A promising therapeutic option while awaiting future therapies?"],"prefix":"10.1016","author":[{"given":"Francesca","family":"Vittone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Autiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Angela","family":"Malerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Grolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dalla Vestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vasdi.2026.09.001_bib0240","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0245","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0250","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamacardio.2025.5043","article-title":"Thirty-year risk of cardiovascular disease among healthy women according to clinical thresholds of lipoprotein(a)","volume":"11","author":"Nordestgaard","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0260","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0265","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"ESC\/EAS Scientific Document Group.2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0270","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0310","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/eurheartjsupp\/suag048","article-title":"Focus on lipoprotein(a)","volume":"28","author":"Biolo","year":"2026","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0315","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0320","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0325","doi-asserted-by":"crossref","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0330","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0335","doi-asserted-by":"crossref","first-page":"120420","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0345","first-page":"CD009744","article-title":"Niacin for primary and secondary prevention of cardiovascular events","volume":"6","author":"Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2024.09.013","article-title":"Obicetrapib demonstrates significant deductions of LP(A) on top of high-intensity statins","volume":"278","author":"Tsimikas","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0355","first-page":"144","article-title":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: a systematic review and meta-analysis","volume":"51","author":"Kayani","year":"2026","journal-title":"Vasc Dis (Paris)"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0365","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0370","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"335","author":"Ballantyne","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0375","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.vasdi.2026.09.001_bib0380","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0385","doi-asserted-by":"crossref","first-page":"34111","DOI":"10.1074\/jbc.274.48.34111","article-title":"Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription","volume":"274","author":"Kagawa","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0390","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","article-title":"Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases","volume":"48","author":"Akaike","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0395","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.003","article-title":"Effect of aspirin on lipoprotein(a) in patients with ischemic stroke","volume":"16","author":"Ranga","year":"2007","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0400","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0405","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0410","doi-asserted-by":"crossref","first-page":"100754","DOI":"10.1016\/j.jacadv.2023.100754","article-title":"Updated lipoprotein(a) genomic risk score and aspirin for primary prevention of cardiovascular events","volume":"3","author":"Yu","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0415","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1160\/TH09-01-0037","article-title":"Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study","volume":"102","author":"Shiffman","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0420","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1055\/s-0043-1771188","article-title":"Inverse association of lipoprotein(a) on long-term bleeding risk in patients with coronary heart disease: insight from a multicenter cohort in Asia","volume":"124","author":"Wang","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0425","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1093\/eurheartj\/ehag161","article-title":"Aspirin for elevated lipoprotein(a) in primary prevention: evidence mounting","volume":"47","author":"Lacaze","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0430","doi-asserted-by":"crossref","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0435","doi-asserted-by":"crossref","first-page":"100674","DOI":"10.1016\/j.ajpc.2024.100674","article-title":"Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0440","doi-asserted-by":"crossref","first-page":"102068","DOI":"10.1016\/j.jacadv.2025.102068","article-title":"Primary prevention aspirin, lipoprotein(a), and cardiorenal outcomes in chronic kidney disease: chronic renal insufficiency cohort","volume":"4","author":"Razavi","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0445","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1093\/eurheartj\/ehag018","article-title":"Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis","volume":"47","author":"Razavi","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0450","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf547","article-title":"Aspirin use and the risk for cardiovascular disease by lipoprotein(a) levels: a multi-cohort study","author":"Colantonio","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0455","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40256-026-00795-8","article-title":"Impact of aspirin on primary prevention of cardiovascular events in patients with elevated lipoprotein(a): a systematic review and meta-analysis","volume":"26","author":"Caldeira","year":"2026","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0460","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag207","article-title":"Efficacy and safety of aspirin for primary prevention in adults with elevated lipoprotein(a) or genetic susceptibility via LPA gene variants: a systematic review and meta-analysis","author":"Lopes","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0465","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.09.001_bib0470","unstructured":"https:\/\/www.novartis.com \u203a news."}],"container-title":["Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305065812600275X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305065812600275X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:30Z","timestamp":1792097070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305065812600275X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S305065812600275X"],"URL":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.09.001","relation":{},"ISSN":["3050-6581"],"issn-type":[{"value":"3050-6581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for primary prevention in patients with high lipoprotein(a): A promising therapeutic option while awaiting future therapies?","name":"articletitle","label":"Article Title"},{"value":"Vascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}